Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Denosumab for Breast Cancer With Bone Mets
NCT01952054 · M.D. Anderson Cancer Center · PHASE2 · terminated · last registry update 2019-11-22 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-01-18Also stopped (withdrawn): Borstkanker Onderzoek Groep, Denosumab 120 mg + Denosumab 60 mg (NCT03532087)
- 2020-01-02Results posted on the registry: Hope Rugo, MD, Denosumab (NCT01545648)
- 2020-01-02Also stopped (terminated): Hope Rugo, MD, Denosumab (NCT01545648)
- 2019-09-09Results posted on the registry: Amgen, Denosumab (NCT01419717)
- 2018-11-27Also stopped (terminated): Jules Bordet Institute, Denosumab (NCT01864798)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision